Cingulate Inc Dossier
Qualitative Analysis
Business overview
Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. The company's primary focus is on the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and anxiety disorders. Its lead product candidate, CTx-1301 (dexmethylphenidate HCl), is a once-daily, multi-core tablet designed to deliver three precisely timed releases of active medication across the day to provide rapid onset and entire active-day duration without the need for booster doses. The PTR platform incorporates a proprietary Erosion Barrier Layer (EBL) licensed from BDD Pharma (marketed as Oralogik) that controls drug release at precise, pre-defined times.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Addressing the specific Chemistry, Manufacturing, and Controls (CMC) information requests raised by the FDA in its June 2, 2026 Complete Response Letter (CRL) in order to promptly resubmit the NDA for CTx-1301.
Expected impact: Resolves outstanding regulatory hurdles to secure FDA approval for CTx-1301 without requiring new clinical safety or efficacy trials.
Advancing commercial readiness activities, including market access, payer engagement, and deploying an AI-augmented omnichannel marketing infrastructure in partnership with Indegene and IQVIA.
Expected impact: Optimizes prescriber reach and commercial uptake upon potential FDA approval of CTx-1301.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Bend Bio Sciences serves as the exclusive commercial manufacturer of CTx-1301 in the United States through 2028, securing U.S. manufacturing capacity and supply chain reliability ahead of launch.
Terms: Cingulate has committed to purchasing 100% of its overall U.S. commercial supply of CTx-1301 from Bend Bio Sciences, subject to FDA approval.
Delivers an integrated, AI-driven omnichannel marketing and commercialization platform to optimize prescriber reach, payer access, and patient support at launch.
Terms: Established on a fee-for-service basis, allowing Cingulate the flexibility to find other commercialization partners if better terms emerge.